Kairos Pharma, Ltd. KAPA
Set alert
0.47 USD 0.00 0.00%
At close
0.49 +0.01 +2.96%
Pre-market · Nov 3, 8:56 AM ET
Day range unavailable
0.4735 52-week range 7.28
- YTD
- -90.47%
- 1 year
- -93.30%
- Open
- —
- Prev close
- 0.4735
- Mkt cap
- 1.60M
- Vol
- 0
- Avg vol
- 369.64K
- EPS
- -1.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -7.46
- Beta
- 0.00
- Short ratio
- 0.13
- Inst. own
- 0.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.54
- 200-d avg
- 1.60
- 1y target
- 9.00
Financial health
Altman Z-Score
-5.32 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 3
Valuation
P/E -2.4×
FY 2020 5y median -15.3× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 2.1×
FY 2020 5y median -13.0× FY 2025
P/FCF -3.8×
FY 2020 5y median -4.4× FY 2025
EV/EBITDA -1.6×
FY 2020 5y median -17.7× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -26.3%
FY 2020 5y median -1.3% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -85.9%
FY 2020 5y median 87.2% FY 2025
ROIC -87.9%
FY 2020 5y median 96.3% FY 2025
ROA -83.3%
FY 2020 5y median -101.4% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -137.8%
FY 2020 FY 2025
EPS (diluted) -30.4%
FY 2020 FY 2025
Free Cash Flow 13.0%
FY 2020 FY 2025
Financial Health
Current Ratio 27.1×
FY 2020 5y median 0.3× FY 2025
Quick Ratio 27.1×
FY 2020 5y median 0.3× FY 2025
Debt / Equity 0.0×
FY 2020 5y median -0.3× FY 2025
Net Debt / EBITDA 0.8×
FY 2020 5y median -0.2× FY 2025
Interest Coverage 0.0×
FY 2020 5y median -2.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31